2628.9000 62.60 (2.44%)
NSE Aug 04, 2025 15:40 PM
Volume: 540.8K
 

2628.90
2.44%
Motilal Oswal
MANKIND has a strategic roadmap for growth through expansion in high entry barrier innovative product launches in the chronic/consumer segment and other adjacencies, transitioning from sexual wellness to consumer wellness in the over-the counter (OTC) space.
Number of FII/FPI investors increased from 640 to 648 in Jun 2025 qtr.
More from Mankind Pharma Ltd.
Recommended